Immunome, Inc. (NASDAQ:IMNM) Receives Average Rating of "Buy" from Analysts

Shares of Immunome, Inc. (NASDAQ:IMNM - Get Free Report) have earned an average recommendation of "Buy" from the six ratings firms that are covering the firm, MarketBeat.com reports. Six analysts have rated the stock with a buy recommendation. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $23.33.

A number of equities research analysts have recently issued reports on the stock. Lifesci Capital assumed coverage on shares of Immunome in a research note on Tuesday, March 11th. They issued an "outperform" rating and a $20.00 price target on the stock. Guggenheim dropped their price target on shares of Immunome from $35.00 to $25.00 and set a "buy" rating on the stock in a research note on Thursday, March 20th. Wedbush reissued an "outperform" rating and issued a $21.00 target price (down from $33.00) on shares of Immunome in a research report on Tuesday, May 13th. Lake Street Capital started coverage on shares of Immunome in a research report on Wednesday, April 2nd. They set a "buy" rating and a $23.00 price objective on the stock. Finally, Stephens restated an "overweight" rating and set a $30.00 price target on shares of Immunome in a research note on Thursday, March 20th.

Insider Activity at Immunome

In related news, Director Jean Jacques Bienaime acquired 7,000 shares of the company's stock in a transaction that occurred on Monday, March 24th. The stock was purchased at an average price of $8.21 per share, for a total transaction of $57,470.00. Following the transaction, the director now owns 23,615 shares in the company, valued at $193,879.15. This trade represents a 42.13% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Clay B. Siegall bought 137,100 shares of the stock in a transaction on Wednesday, March 26th. The stock was purchased at an average cost of $7.29 per share, with a total value of $999,459.00. Following the completion of the purchase, the chief executive officer now directly owns 806,736 shares in the company, valued at $5,881,105.44. This trade represents a 20.47% increase in their position. The disclosure for this purchase can be found here. Insiders bought 156,400 shares of company stock valued at $1,160,495 in the last ninety days. Corporate insiders own 8.60% of the company's stock.

Institutional Investors Weigh In On Immunome

A number of hedge funds and other institutional investors have recently made changes to their positions in IMNM. BNP Paribas Financial Markets purchased a new position in Immunome during the fourth quarter worth about $70,000. KLP Kapitalforvaltning AS acquired a new position in shares of Immunome during the 4th quarter valued at about $75,000. AlphaQuest LLC lifted its holdings in shares of Immunome by 786,700.0% during the 4th quarter. AlphaQuest LLC now owns 7,868 shares of the company's stock worth $84,000 after acquiring an additional 7,867 shares during the period. Tower Research Capital LLC TRC lifted its holdings in shares of Immunome by 482.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 8,608 shares of the company's stock worth $91,000 after acquiring an additional 7,129 shares during the period. Finally, Aquatic Capital Management LLC acquired a new stake in shares of Immunome in the fourth quarter worth approximately $95,000. Hedge funds and other institutional investors own 44.58% of the company's stock.

Immunome Stock Performance

Shares of IMNM traded up $0.23 during mid-day trading on Friday, hitting $8.86. 77,066 shares of the company were exchanged, compared to its average volume of 915,689. Immunome has a 1-year low of $5.15 and a 1-year high of $16.81. The stock has a market cap of $770.93 million, a price-to-earnings ratio of -1.10 and a beta of 2.00. The company has a 50 day moving average of $7.60 and a 200-day moving average of $9.60.

Immunome (NASDAQ:IMNM - Get Free Report) last issued its earnings results on Monday, May 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.66) by $0.14. Immunome had a negative return on equity of 48.63% and a negative net margin of 3,014.59%. The business had revenue of $2.93 million during the quarter, compared to the consensus estimate of $0.46 million. Research analysts anticipate that Immunome will post -2.21 earnings per share for the current fiscal year.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.